Ambenonium
- Atc Codes:N07AA30
- CAS Codes:115-79-7#52022-31-8#7648-98-8
- PHARMGKB ID:115-79-7#52022-31-8#7648-98-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Czech Republic: Mytelase; France: Mytelase; Hungary: Mytelase; Poland: Mytelase; Sweden: Mytelase.
North America
USA: Mytelase.
Asia
Japan: Mytelase.
Drug combinations
Chemistry
Ambenonium Chloride: C~28~H~42~Cl~4~N~4~O~2~. Mw: 608.47. (1) Benzenemethanaminium, N,N’-[(1,2-dioxo-1,2-ethanediyl)bis(imino-2,1-ethanediyl)]bis[2-chloro-N,N-diethyl-, dichloride; (2) [Oxalylbis(iminoethylene)]bis[(o-chlorobenzyl)diethylammonium] dichloride. CAS-115-79-7; CAS-52022-31-8 (tetrahydrate); CAS-7648-98-8 (ambenonium).
Pharmacologic Category
Parasympathomimetic (Cholinergic) Agents. Anticholinesterases. (ATC-Code: N07AA30).
Mechanism of action
Therapeutic use
Treatment of myasthenia gravis.
Pregnancy and lactiation implications
Use in pregnant women requires that the possible benefits be weighed against the potential risks. Administration during lactation is not recommended.
Unlabeled use
Contraindications
Co-administration with atropine or other belladonna alkaloids. Patients receiving mecamylamine.
Warnings and precautions
Anticholinergic insensitivity may develop. Use with caution in asthma, bradycardia, hyperthyroidism, Parkinson’s disease, peptic ulcer disease, seizures or in urinary tract obstruction. Differentiation of cholinergic/myasthenia crisis is critical.